News coverage about Ignyta (NASDAQ:RXDX) has trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ignyta earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.6220513602748 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of analysts recently commented on the company. Zacks Investment Research raised Ignyta from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research report on Wednesday, January 10th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $27.00 price target on shares of Ignyta in a research report on Friday, February 9th. ValuEngine raised Ignyta from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. SunTrust Banks downgraded Ignyta from a “buy” rating to a “hold” rating and increased their price target for the company from $25.00 to $27.00 in a research report on Tuesday, December 26th. Finally, Ladenburg Thalmann Financial Services downgraded Ignyta from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 26th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $27.00.

Ignyta (NASDAQ:RXDX) opened at $26.95 on Wednesday. Ignyta has a twelve month low of $5.80 and a twelve month high of $27.10. The firm has a market capitalization of $1,790.00, a price-to-earnings ratio of -9.94 and a beta of 184.87. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.34.

TRADEMARK VIOLATION WARNING: This story was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://theolympiareport.com/2018/02/14/ignyta-rxdx-earns-daily-coverage-optimism-score-of-0-19.html.

Ignyta Company Profile

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Insider Buying and Selling by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.